Key facts
- Developer of a mammalian cell line discovery platform designed to enhance the design of cell lines for biomanufacturing and therapeutics.
- It has raised $59.5M; the latest was Accelerator/Incubator in Apr 2025.
- Notable investors include Y Combinator, BoxGroup, Liquid 2 Ventures, SV Angel, First Round Capital — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for 64x Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for 64x Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 64x Bio
Developer of a mammalian cell line discovery platform designed to enhance the design of cell lines for biomanufacturing and therapeutics. The company's platform helps to bring cell and gene therapies to patients effectively and provides purpose-built genetically engineered cell lines for the efficiency of viral vector production, enabling pharmaceutical and biotechnology companies to improve manufacturing capacity and reduce manufacturing costs.
- Sector
- Healthcare
- HQ
- Brisbane, CA, United States
- Founded
- 2017
- Employees
- 24
- Website
- 64xbio.com/
- Ownership
- Privately Held (backing)
64x Bio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.